# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN
- Date: 2026-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review: A1c, blood pressure, weight and semaglutide dose. **S**

## History of present illness

Mr. Frazier returns five weeks after his eight-week review. He has taken semaglutide 0.5 mg weekly for seven weeks without nausea. He takes amlodipine 10 mg; home readings average 128/78, and he has no ankle swelling. He has had no alcohol. He has lost 4.1 kg since intake. He missed his eye clinic appointment because it fell on the evening of a fight card at his gym, and it has not yet been rebooked. **S**

| Element | Detail |
|---|---|
| Semaglutide | 0.5 mg weekly for seven weeks; no side effects |
| Home blood pressure | Average 128/78 on amlodipine 10 mg |
| Weight | 99.9 kg, down 4.1 kg |
| Eye examination | Missed; not rebooked |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No new blurring or floaters in the right eye |
| Gastrointestinal | Negative | No nausea or abdominal pain |
| Cardiovascular | Negative | No ankle swelling |

3 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years **S**
- Lisinopril 20 mg oral tablet, one tablet daily; taken for years **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Amlodipine 10 mg oral tablet, one tablet daily **S**
- Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 99.9 kg; BMI 30.2 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 7.3% (high). All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 8.4% (high) at baseline, 7.3% (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/78, pulse 74; weight 99.9 kg, BMI 30.2 |
| Cardiovascular | No ankle edema |
| Abdomen | Soft; no ascites |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes** (E11.65). A1c 7.3% from 8.4%; no low blood sugar. The dilated eye examination planned at intake has not happened; it matters more now because a rapid fall in A1c on a GLP-1 receptor agonist can briefly worsen existing diabetic retinopathy. He has no new eye symptoms. **S**
   - Increase semaglutide to 1 mg weekly.
   - Eye clinic appointment rebooked by the clinic on a day he chose, with a reminder call.
2. **Hypertension** (I10). At goal: 126/78 in the clinic and 128/78 at home. **S**
   - Continue lisinopril 20 mg and amlodipine 10 mg.
3. **Obesity** (E66.811). 4% weight loss; the goal for the liver is 7 to 10%. **S**
   - Continue smaller portions, less salt and walks after dinner.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Completed today | 7.3% from 8.4% |
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 126/78 in the clinic; home average 128/78; weight 99.9 kg |
| Medication safety | Semaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptoms | At each dose step | Completed today | 0.5 mg for seven weeks without side effects; increased to 1 mg |
| Medication safety | Low blood sugar review and medicine tolerability | Every visit | Completed today | No low blood sugar |
| Examination | Dilated eye examination | At the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonist | Deferred | Planned at intake but not done three months later: he missed the appointment, and it was not rebooked. No harm is known: he has no new eye symptoms, and the later examination found no retinopathy. Corrective action: the clinic rebooked it on a day he chose, with a reminder call, before the A1c falls further |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2021) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Up to date | Stable five weeks ago; next at seven months |
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Up to date | Next in September |
| Self-management | Weight loss of 7 to 10% | Each visit | Completed today | 4% so far |
| Self-management | Alcohol abstinence | Every visit | Completed today | No alcohol |
| Self-management | Diabetes self-management education | At the start of care and yearly | Completed today | Series of classes completed |

## Goal progress

- A1c below 7% within six to nine months, without low blood sugar. In progress; target 2026-09-14. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home. In progress; target 2026-09-14. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-13: 132 to 68 mg/dL on atorvastatin. **S**
- Weight loss of 7 to 10% for liver health within a year. In progress; target 2026-09-14. **S**
- Liver cancer surveillance by ultrasound with AFP every six months, on time. In progress; target 2026-09-14. **S**
- No alcohol, to protect the liver. In progress; target 2026-09-14. **S**

## Medication changes

- Stopped: Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly **S**
- Started: Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly **S**

## Guideline basis

- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023), American Association for the Study of Liver Diseases (Hepatology 2023;77(5))
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023), American Association for the Study of Liver Diseases (Hepatology 2023;78(6))
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Eye clinic next month. Preventive visit in eight weeks. Seven-month review in September with the surveillance ultrasound and AFP. **S**
- Next scheduled visit 2026-07-13: periodic adult preventive visit. **S**
